Lassen Therapeutics Commences Dosing in Phase 1 Clinical Study of LASN01, a First-in-Class Interleukin-11 Receptor-Blocking Antibody October 3, 2022
Lassen Therapeutics Presents New Preclinical Data on IL-11 Receptor-blocking as a Novel Therapeutic Approach for Skin Fibrosis June 16, 2022
Lassen Therapeutics Presents Data Demonstrating Preclinical Anti-fibrotic Effect of LASN01, a Novel IL-11 Receptor-Blocking Antibody, at the American Thoracic Society 2022 Annual Meeting May 31, 2022
Lassen Therapeutics Announces the Appointment of a Highly Experienced Biotech Executive to its Board of Directors and the Expansion of its Scientific and Clinical Advisory Board with Leading Experts in Pulmonary Fibrosis and Clinical Development October 8, 2021
